Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
| ▸ | CTSA | P10619 | 3/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | GRK6 | P43250 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16319386 | 0.89 | CTSA (0.43) | FFAR1CTSADHODHXDHGRK6 | |
| SCHEMBL16319427 | 0.82 | FFAR1 (0.44) | FFAR1CTSADHODHXDHIDH2 | |
| SCHEMBL16319385 | 0.82 | FFAR1 (0.42) | FFAR1CTSADHODHGRK6KDM4E | |
| SCHEMBL16318846 | 0.77 | FFAR1 (0.43) | FFAR1CTSAXDHGRK6KDM4E | |
| SCHEMBL16319387 | 0.74 | FFAR1 (0.42) | FFAR1CTSAIDH2 | |
| SCHEMBL16319092 | 0.71 | AR (0.39) | FFAR1DHODHXDHIDH2 | |
| SCHEMBL17418806 | 0.70 | FFAR1 (0.50) | FFAR1CTSADHODHIDH2 | |
| SCHEMBL16318882 | 0.69 | FFAR1 (0.43) | FFAR1CTSADHODHGRK6KDM4E | |
| SCHEMBL16319368 | 0.68 | FFAR1 (0.39) | FFAR1DHODHGRK6KDM4ECYP2C9 | |
| SCHEMBL16319342 | 0.68 | FFAR1 (0.45) | FFAR1GRK6KDM4ECYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181186-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150045378-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2816032-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045378-A1 | AROMATIC RING COMPOUND | GPR119, GPR27, GPR4 | FFAR1 31/4885CTSA 3367/4885DHODH 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.